Failure To Invest In Drug Repositioning Is Frustrating, Says EU Rare Disease Patients Group
Executive Summary
Yann Le Cam, who heads the EU network of rare disease patient organizations, is calling for innovative solutions to support the 'repositioning' of existing and new medicines that could potentially treat orphan conditions but are not developed by companies due to business considerations.